Papilledema Overview

Save information for later
Sign Up

Learn About Papilledema

What is the definition of Papilledema?
Papilledema is a condition in which increased pressure in or around the brain (intracranial pressure) causes swelling of the part of the optic nerve inside the eye (optic disc). Symptoms of increased intracranial pressure include headache or nausea and vomiting. Vision problems are not common initially, but may include short flickers of gray vision, blurred or double vision, and decreased field of vision or ability to see colors. Both eyes are usually affected. Papilledema by definition is caused by increased cranial pressure. Diagnosis includes a thorough eye exam by an ophthalmologist. Brain imaging studies (for example CT scan or MRI) are used to find the cause of the increased intracranial pressure.
What are the alternative names for Papilledema?
  • Papilledema
  • Choked disk
  • Edema of the optic disc
Who are the top Papilledema Local Doctors?
Experienced in Papilledema
Dr. David A. Boes
Ophthalmology
Experienced in Papilledema
Dr. David A. Boes
Ophthalmology

Boes Eye Care

2800 11th Ave S, 14 David A Boes Md, 
Great Falls, MT 
 (2.1 mi)
406-455-2020
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Boes is an Ophthalmologist in Great Falls, Montana. Dr. Boes and is rated as an Experienced provider by MediFind in the treatment of Papilledema. His top areas of expertise are Cataract, Dry Eye Syndrome, Optic Atrophy Type 1, and Optic Nerve Atrophy. Dr. Boes is currently accepting new patients.

Experienced in Papilledema
Dr. Brandon Mccafferty
Ophthalmology
Experienced in Papilledema
Dr. Brandon Mccafferty
Ophthalmology

Great Falls Clinic

3000 15th Avenue South, 
Great Falls, MT 
 (12.9 mi)
Experience:
11+ years
Languages Spoken:
English
See accepted insurances

Brandon Mccafferty is an Ophthalmologist in Great Falls, Montana. Dr. Mccafferty has been practicing medicine for over 11 years and is rated as an Experienced provider by MediFind in the treatment of Papilledema. His top areas of expertise are Cataract, Oculocutaneous Albinism Type 1, Oculocutaneous Albinism Type 2, and Oculocutaneous Albinism.

 
 
 
 
Learn about our expert tiers
Learn More
Experienced in Papilledema
Dr. Angela S. Watkins
Ophthalmology
Experienced in Papilledema
Dr. Angela S. Watkins
Ophthalmology

Medical Eye Specialists PC

205 W Main St, 
Belgrade, MT 
 (119.5 mi)
406-587-1245
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Angela Watkins is an Ophthalmologist in Belgrade, Montana. Dr. Watkins and is rated as an Experienced provider by MediFind in the treatment of Papilledema. Her top areas of expertise are Cataract, Meibomianitis, Entropion, and Chalazion. Dr. Watkins is currently accepting new patients.

View All Doctors
What are the latest Papilledema Clinical Trials?
China Faricimab Real World Evidence: Evaluation of Faricimab Effectiveness, Safety and Treatment Pattern, in Diabetic Macular Edema, Retinal Vein Occlusion and Neovascular Age-Related Macular Degeneration: The Farseeing Study
China Faricimab Real World Evidence: Evaluation of Faricimab Effectiveness, Safety and Treatment Pattern, in Diabetic Macular Edema, Retinal Vein Occlusion and Neovascular Age-Related Macular Degeneration: The Farseeing Study
Enrollment Status: Recruiting
Publish Date: January 29, 2025
Intervention Type: Drug

Summary: The Farseeing Study will explore long-term effectiveness, safety, and treatment patterns among patients being treated with faricimab in real-world, routine clinical practice in China. It is a primary data collection, non-interventional, prospective and retrospective, multi-center study designed to collect real-world, long-term data to gain clinical evidence on faricimab, by observing cohorts of pa...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Efficacy of Switching to Aflibercept 8mg in Patients with Neovascular AMD Showing Limited Response to Faricimab or Aflibercept 2mg
Efficacy of Switching to Aflibercept 8mg in Patients with Neovascular AMD Showing Limited Response to Faricimab or Aflibercept 2mg
Enrollment Status: Recruiting
Publish Date: November 12, 2024
Intervention Type: Drug
Study Phase: Phase 4

Summary: The treatment landscape for neovascular AMD has evolved with various anti-VEGF agents since 2006. Ranibizumab initially led the way, but its limited efficacy in reducing retinal edema paved the way for aflibercept in 2011, which became globally popular for its effectiveness and safety. Yet, aflibercept did not fully meet all patients' needs. In 2019, brolucizumab showed promising anatomical result...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center